Home  |  About us  |  Editorial board  |  Ahead of print  | Current issue  |  Archives  |  Submit article  |  Instructions |  Search  |   Subscribe  |  Advertise  |  Contacts  |  Login 
  Users Online: 790Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
ORIGINAL ARTICLE

Assessing knowledge, attitude, and practices of health-care providers toward pharmacovigilance and adverse drug reaction reporting at a comprehensive cancer center in Jordan


 Department of Pharmacy, Center for Drug Policy and Technology Assessment, King Hussein Cancer Center, Amman, Jordan

Correspondence Address:
Abeer Ahmad Al Rabayah,
Department of Pharmacy, King Hussein Cancer Center, Queen Rania Street Next to The University of Jordan, P. O. Box 1269, Amman 11941
Jordan
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/picr.PICR_4_18

Background and Objective: Cancer patients are more likely to experience adverse drug reactions (ADRs) than other patients, because of both the complexity of the treatment regimens and the severity of disease. The objectives of this study were to determine the knowledge, attitude, and practice of health-care providers toward pharmacovigilance and ADR reporting, barriers to ADR reporting, and the association between the demographics of health-care providers and their knowledge and attitude toward reporting. Materials and Methods: A cross-sectional survey was conducted at the King Hussein Cancer Center. A self-administered questionnaire was distributed to dispensary pharmacists, clinical pharmacists, physicians, and nurses. Descriptive analysis was used, with testing for associations between variables. Results: Of the 373 questionnaires, 306 were returned (response rate, 82%). Pharmacists and nurses were more knowledgeable than physicians; however, all participants had a highly positive attitude toward pharmacovigilance and ADR reporting, with a mean score of 3.87 out of 5. The main knowledge gaps were filling in an ADR reporting form, assessing the severity of ADRs, and differentiating between ADRs and adverse events. The main barriers to ADR reporting (37.5% of responses) were considered to be lack of training and of understanding reporting rules. No associations were found with age, gender, years of experience, attitude, or knowledge. Conclusion and Recommendations: Understanding of pharmacovigilance and ADR reporting could further be improved among health-care providers at our center.
    
 

  Search Pubmed for
 
    -  Al Rabayah AA
    -  Hanoun EM
    -  Al Rumman RH
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed197    
    PDF Downloaded9    

Recommend this journal